Treated T Cells Followed by a Stem Cell Transplant in Treating Patients With Multiple Myeloma

DISEASE CHARACTERISTICS:

* Diagnosis of multiple myeloma

  * Candidate for high-dose chemotherapy and autologous stem cell transplantation
* No definite morphologic evidence of myelodysplasia on pretreatment bone marrow

PATIENT CHARACTERISTICS:

* ECOG performance status (PS) 0-2 or Karnofsky PS 70-100%
* ANC \> 500/mm\^3
* Platelet count ≥ 75,000/mm\^3
* Total bilirubin ≤ 2.0 mg/dL
* AST and ALT ≤ 3 times upper limit of normal
* Creatinine ≤ 2.0 mg/dL
* LVEF ≥ 45%
* Corrected pulmonary diffusion capacity ≥ 50%
* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use effective contraception
* No uncontrolled infections or other severe medical problems such as adrenal dysfunction
* No other active malignancy (except for nonmelanoma skin cancer) that requires myelosuppressive chemotherapy or radiotherapy
* No HIV infection

PRIOR CONCURRENT THERAPY:

* See Disease Characteristics
* On-chemotherapy induction with thalidomide or lenalidomide with dexamethasone is allowed
* No prior stem cell transplantation
* No more than 2 prior treatment regimens (including the one during which patients undergo leukapheresis for T-cells)
* No more than 4 courses of lenalidomide in combination with other agents or as a single agent over a 1-year period
* No other concurrent immunotherapy, radiotherapy, chemotherapy, or anti-myeloma therapy at the time of the anti-CD3 x anti-CD20-armed ATC infusion